Oncolytics Biotech Inc. (ONCY)
0.79
-0.05 (-5.78%)
At close: Jan 17, 2025, 3:59 PM
0.79
-0.40%
After-hours Jan 17, 2025, 07:59 PM EST
Company Description
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer.
Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies.
Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC.
The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Oncolytics Biotech Inc.
| Country | CA |
| IPO Date | Oct 5, 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Wayne F. Pisano M.B.A. |
Contact Details
Address: 322 11th Avenue SW Calgary, AB CA | |
| Website | https://www.oncolyticsbiotech.com |
Stock Details
| Ticker Symbol | ONCY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001129928 |
| CUSIP Number | 682310875 |
| ISIN Number | CA6823108759 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Matthew C. Coffey M.B.A., Ph.D. | President, Chief Executive Officer & Director (Leave of Absence) |
| Wayne F. Pisano M.B.A. | Interim Chief Executive Officer & Chairman of the Board |
| Kirk J. Look C.A., CA | Chief Financial Officer |
| Allison Hagerman P.Eng., P.M.P. | Vice President of Product Development |
| Amy Goodowitz Levin B.S.N., R.N. | Vice President of Clinical Operations |
| Dr. Thomas C. Heineman M.D., Ph.D. | Chief Medical Officer |
| John Mark Lievonen B.B.A., F.C.A., FCPA, LLD, M.B.A. | Consultant |
| Jon Patton | Director of Investor Relations & Communication |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 15, 2025 | 6-K | Filing |
| Dec 23, 2024 | 6-K | Filing |
| Dec 18, 2024 | 6-K | Filing |
| Dec 03, 2024 | 6-K | Filing |
| Nov 12, 2024 | 6-K | Filing |
| Nov 12, 2024 | 6-K | Filing |
| Nov 12, 2024 | 6-K | Filing |
| Oct 04, 2024 | 6-K | Filing |
| Sep 19, 2024 | 6-K | Filing |
| Sep 06, 2024 | 6-K | Filing |